These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 19075639)
21. A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis. Fan S; Ross C; Mitra S; Kalra P; Heaton J; Hunter J; Plone M; Pritchard N Nephrol Dial Transplant; 2009 Dec; 24(12):3794-9. PubMed ID: 19666658 [TBL] [Abstract][Full Text] [Related]
23. Randomized controlled trial of bixalomer versus sevelamer hydrochloride in hemodialysis patients with hyperphosphatemia. Akizawa T; Origasa H; Kameoka C; Kaneko Y; Kawasaki S; Ther Apher Dial; 2014 Apr; 18(2):122-31. PubMed ID: 24720402 [TBL] [Abstract][Full Text] [Related]
24. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Suki WN; Zabaneh R; Cangiano JL; Reed J; Fischer D; Garrett L; Ling BN; Chasan-Taber S; Dillon MA; Blair AT; Burke SK Kidney Int; 2007 Nov; 72(9):1130-7. PubMed ID: 17728707 [TBL] [Abstract][Full Text] [Related]
25. A randomized trial of JTT-751 versus sevelamer hydrochloride in patients on hemodialysis. Yokoyama K; Akiba T; Fukagawa M; Nakayama M; Sawada K; Kumagai Y; Chertow GM; Hirakata H Nephrol Dial Transplant; 2014 May; 29(5):1053-60. PubMed ID: 24376274 [TBL] [Abstract][Full Text] [Related]
26. Evaluation of morbidity and mortality data related to cardiovascular calcification from calcium-containing phosphate binder use in patients undergoing hemodialysis. Mason MA; Shepler BM Pharmacotherapy; 2010 Jul; 30(7):741-8. PubMed ID: 20575637 [TBL] [Abstract][Full Text] [Related]
27. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study. Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283 [TBL] [Abstract][Full Text] [Related]
28. Clinical efficacy, safety and anti-inflammatory activity of two sevelamer tablet forms in patients on low-flux hemodialysis. Tzanno-Martins C; Biavo BM; Ferreira-Filho O; Ribeiro-Junior E; João-Luiz MV; Degaspari S; Scavone C; Kawamoto E Int J Immunopathol Pharmacol; 2014; 27(1):25-35. PubMed ID: 24674676 [TBL] [Abstract][Full Text] [Related]
30. Chronic acid-base perturbations in hemodialysis patients treated with sevelamer hydrochloride: a two-year follow-up study. Vlahakos DV; Retsa K; Kalogeropoulou S; Katsoudas S; Bacharaki D; Agroyannis B Artif Organs; 2007 Dec; 31(12):892-5. PubMed ID: 17924988 [TBL] [Abstract][Full Text] [Related]
31. Does concomitant administration of sevelamer hydrochloride and lanthanum carbonate modify the control of phosphatemia? Senatore M; Coppolino G; Papalia T; Greco R; Lofaro D; Bonofiglio R Eur Rev Med Pharmacol Sci; 2011 Nov; 15(11):1352-4. PubMed ID: 22195373 [No Abstract] [Full Text] [Related]
32. Differential effects of phosphate binders on pre-dialysis serum bicarbonate in end-stage kidney disease patients on maintenance haemodialysis. Thet Z; Win AK; Pedagogos E; Beavis J; Crikis S; Nelson C BMC Nephrol; 2013 Oct; 14():205. PubMed ID: 24079654 [TBL] [Abstract][Full Text] [Related]
33. Sevelamer is cost-saving vs. calcium carbonate in non-dialysis-dependent CKD patients in italy: a patient-level cost-effectiveness analysis of the INDEPENDENT study. Ruggeri M; Cipriani F; Bellasi A; Russo D; Di Iorio B Blood Purif; 2014; 37(4):316-24. PubMed ID: 25171148 [TBL] [Abstract][Full Text] [Related]
34. Lanthanum carbonate versus sevelamer hydrochloride: improvement of metabolic acidosis and hyperkalemia in hemodialysis patients. Filiopoulos V; Koutis I; Trompouki S; Hadjiyannakos D; Lazarou D; Vlassopoulos D Ther Apher Dial; 2011 Feb; 15(1):20-7. PubMed ID: 21272248 [TBL] [Abstract][Full Text] [Related]
35. A randomized, parallel, open-label study to compare once-daily sevelamer carbonate powder dosing with thrice-daily sevelamer hydrochloride tablet dosing in CKD patients on hemodialysis. Fishbane S; Delmez J; Suki WN; Hariachar SK; Heaton J; Chasan-Taber S; Plone MA; Moe S Am J Kidney Dis; 2010 Feb; 55(2):307-15. PubMed ID: 20042256 [TBL] [Abstract][Full Text] [Related]
36. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH]. Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625 [TBL] [Abstract][Full Text] [Related]
37. A comparative review of the efficacy and safety of established phosphate binders: calcium, sevelamer, and lanthanum carbonate. Sprague SM Curr Med Res Opin; 2007 Dec; 23(12):3167-75. PubMed ID: 17991307 [TBL] [Abstract][Full Text] [Related]
38. Sevelamer reduces the efficacy of many other drugs. Prescrire Int; 2009 Aug; 18(102):164-5. PubMed ID: 19743578 [TBL] [Abstract][Full Text] [Related]
39. Sevelamer carbonate lowers serum phosphorus effectively in haemodialysis patients: a randomized, double-blind, placebo-controlled, dose-titration study. Chen N; Wu X; Ding X; Mei C; Fu P; Jiang G; Li X; Chen J; Liu B; La Y; Hou F; Ni Z; Fu J; Xing C; Yu X; Huang C; Zuo L; Wang L; Hunter J; Dillon M; Plone M; Neylan J Nephrol Dial Transplant; 2014 Jan; 29(1):152-60. PubMed ID: 24151017 [TBL] [Abstract][Full Text] [Related]
40. The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial. Van Buren PN; Lewis JB; Dwyer JP; Greene T; Middleton J; Sika M; Umanath K; Abraham JD; Arfeen SS; Bowline IG; Chernin G; Fadem SZ; Goral S; Koury M; Sinsakul MV; Weiner DE; Am J Kidney Dis; 2015 Sep; 66(3):479-88. PubMed ID: 25958079 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]